Imidacloprid, Moxidectin

Verify with FDA CVM →

1,792 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,792
Total Reports
74
Deaths Reported
410.0%
Death Rate

Active Ingredients

Imidacloprid, Moxidectin

Administration Routes

TopicalUnknownOtherOralIntraocularOphthalmicNasalIntrauterineRespiratory (Inhalation)Subcutaneous

Species Affected

Dog 1,110
Cat 583
Unknown 48
Human 48
Guinea Pig 1
Rabbit 1
Other 1

Most Affected Breeds

Domestic (unspecified) 390
Crossbred Canine/dog 174
Retriever - Labrador 107
Dog (unknown) 103
Cat (unknown) 99
Unknown 98
Chihuahua 57
Terrier - Yorkshire 54
Shepherd Dog - German 46
Domestic Shorthair 43

Most Reported Reactions

Depression 269
Vomiting 249
Lack of efficacy (endoparasite) - heartworm 178
Hypersalivation 177
Anorexia 139
Behavioural disorder NOS 121
Ataxia 114
Hyperactivity 111
Application site alopecia 108
Accidental exposure 107
Trembling 106
Lack of efficacy (ectoparasite) - flea 104

Outcome Breakdown

Outcome Unknown
391 (60.2%)
Ongoing
119 (18.3%)
Recovered/Normal
66 (10.2%)
Died
62 (9.5%)
Euthanized
12 (1.8%)

Data Summary

Metric Value
Total adverse event reports 1,792
Reports involving death 74
Case-fatality rate (reported events) 410.0%
Distinct species in reports 7
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imidacloprid, Moxidectin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,792 adverse event reports referencing Imidacloprid, Moxidectin, including 74 reports in which the animal died — a 410.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Imidacloprid, Moxidectin. Reported administration routes include Topical, Unknown, Other, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imidacloprid, Moxidectin reports are Dog (1,110 reports), Cat (583 reports), Unknown (48 reports), with Dog accounting for the largest share. Within those species, Domestic (unspecified) (390), Crossbred Canine/dog (174), Retriever - Labrador (107) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imidacloprid, Moxidectin are Depression (269), Vomiting (249), Lack of efficacy (endoparasite) - heartworm (178), Hypersalivation (177). Of the 650 reports with a coded outcome, Outcome Unknown is the leading category at 60.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imidacloprid, Moxidectin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial